Clinical Features

Interstitial Lung Disease – An update from the Irish Lung Fibrosis Association

Interstitial Lung Disease – An update from the Irish Lung Fibrosis Association Written by Nicola Cassidy, Director of the ILFA

Interstitial Lung Disease – An update from the Irish Lung Fibrosis Association

A fascinating set of photographs in the British Museum’s Egyptology section describes how tissue from ancient mummies were studied with modern microscopic and analytical techniques. Lung tissue from one mummy showed histological evidence of lung fibrosis providing evidence that this condition has been around since ancient times, yet only in relatively recent times has research and investment in the study of lung fibrosis experienced exceptional growth.

Lung fibrosis, also known as Interstitial lung diseases (ILD), is an umbrella term for a heterogenous group over 200 types of lung diseases characterised by the process of abnormal tissue repair with resultant disruption and destruction of the lung architecture by scar tissue formation (fibrosis). The most prevalent ILD is idiopathic pulmonary fibrosis (IPF) – a diagnosis of exclusion when all other known ILDs have been ruled out. IPF is a severe, progressive lung disease characterised by breathlessness, hypoxemia, dry and non-productive cough, fatigue, and ultimately respiratory failure. Lung fibrosis is a devastating diagnosis that causes significant physical, mental, and financial burden to patients and their caregivers.1 Psychological distress can develop when lung fibrosis impacts on patients’ abilities to engage in normal activities of daily living and the associated deterioration in quality of life.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free